Those who require insulin pumps could find the approval of the Medtronic MiniMed 670G system by the FDA to be a monumental step forward in helping to improve diabetes care.
The Medtronic MiniMed 670G is designed as the first Hybrid Closed Loop insulin delivery system that will provide substantial support for those with Type 1 diabetes.
The Medtronic MiniMed 670G works by being worn on the body and work to continuously monitor a person's blood-glucose level. Unlike traditional insulin pumps, the Medtronic MiniMed 670G can automatically adjust the level of insulin needed thanks to the SmartGuard HCL algorithm.
The Medtronic MiniMed 670G system features a battery that will last for up to seven days and is expected to be commercially released in the spring of 2017.